Biotech | April 06, 2022
Alvotech and STADA pave way to launching Hukyndra
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
The partnership demonstrates increasing adoption of tetra data to create unrestricted innovation
The new facility is scheduled to start operation in the first half of 2024
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target
Aveir VR is specifically designed to be retrieved when therapy needs to evolve or the device needs to be replaced
Trescal provides precision calibration expertise in every industry, geography and instrument across the world
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
Subscribe To Our Newsletter & Stay Updated
